AI
Saturday, August 17, 2019 12:37:11 PM
$LAHO Hedge Fund Fights Over Stem-Cell Company's Value in Cayman Court
..claiming a proposed $915 million all-share merger would reduce the value of their holdings.
..Global Cord Blood, once known as China Cord Blood, is China’s oldest and largest company that specializes in extracting, processing and storing umbilical cord stem cells that can be used to treat diseases such as leukemia.
https://www.bloomberg.com/amp/news/articles/2019-07-29/hedge-fund-fights-over-stem-cell-company-s-value-in-cayman-court
Chapter 11 Company Profiles
Beike Biotechnology Co. Ltd.
Mesoblast Ltd.
Novartis
https://www.businesswire.com/news/home/20190815005269/en/Worldwide-Stem-Cell-Regenerative-Therapy-Markets-2018-2019
Beike is the world’s largest stem cell provider focusing on the research, development, and clinical translation of adult stem cells.
https://beikebiotech.com
The Wall Street Journal – Hedge-Fund Founder Bolsters Stem-Cell Research With $27 Million Gift
https://nyscf.org/resources/the-wall-street-journal-hedge-fund-founder-bolsters-stem-cell-research-with-27-million-gift/
GSCG established.. alliance.. HANK Bioengineering..Shenzhen, China
..Shenzhen HANK is a biotechnology company established in 2013 by Zhang, an award-winning scientist, microbiologist and virologist, to integrate research, development, production, and sales of biomedical products. Zhang worked at the U.S. Centers for Disease Control from 1991 to 1993, the U.S. National Institute of Health (NIH) from 1993 to 1994, and the U.S. Food and Drug Administration.. Scientific Achievement Award from the USFDA for outstanding achievement in natural killer (NK) cell research, and holds numerous awards for his work in the fields of HIV, HCV, West Nile virus, Japanese encephalitis virus, and quality performance.
..Dr. Zhang expanded on his work in stem cell research and development by launching HANK Bioengineering Co. Ltd. in Shenzhen, China. HANK is a 4,300 square foot (400 square meters) CFDA certified cGMP facility affiliated with HANK Bioengineering Institute’s Cell Biology and Molecular Immunology Laboratories. HANK has established close collaborations with more than five hospitals in China for clinical applications of its cell therapy products.
http://stemcellcenter.net/global-stem-cells-group-announces-alliance-with-hank-bioengineering-co-ltd-in-shenzhen-china/
Effect of NK cell immunotherapy on immune function in patients with hepatic carcinoma: A preliminary clinical study.
ZhangM3
..disease progression at 3 months after treatment was 18.8%, 50.0% and 31.2%, respectively. The total follow-up period was 2-12 months. The median progression-free survival from treatment was 7.5 months. This is the first study on the benefits of HANK cell immunotherapy for hepatic carcinoma These encouraging preliminary observations imply that HANK cell immunotherapy is safe, can improve the immune function of patients with liver cancer, and may even reduce the rate of tumor metastasis and recurrence...
https://www.ncbi.nlm.nih.gov/pubmed/28353401
..Stem Cell Center, Inc. is the world's largest collective support & advisory network of regenerative medicine clinics and and physicians
http://stemcellcenter.net/
Venture capitalists are betting big on one area of regenerative medicine
https://amp.businessinsider.com/venture-capital-interest-in-regenerative-medicine-2017-4
Money is pouring in to a hot new area of science that could change the way we think about aging
https://amp.businessinsider.com/venture-capital-interest-in-regenerative-medicine-2017-4
$LAHO GSCG All directions head to Money$$$
..claiming a proposed $915 million all-share merger would reduce the value of their holdings.
..Global Cord Blood, once known as China Cord Blood, is China’s oldest and largest company that specializes in extracting, processing and storing umbilical cord stem cells that can be used to treat diseases such as leukemia.
https://www.bloomberg.com/amp/news/articles/2019-07-29/hedge-fund-fights-over-stem-cell-company-s-value-in-cayman-court
Chapter 11 Company Profiles
Beike Biotechnology Co. Ltd.
Mesoblast Ltd.
Novartis
https://www.businesswire.com/news/home/20190815005269/en/Worldwide-Stem-Cell-Regenerative-Therapy-Markets-2018-2019
Beike is the world’s largest stem cell provider focusing on the research, development, and clinical translation of adult stem cells.
https://beikebiotech.com
The Wall Street Journal – Hedge-Fund Founder Bolsters Stem-Cell Research With $27 Million Gift
https://nyscf.org/resources/the-wall-street-journal-hedge-fund-founder-bolsters-stem-cell-research-with-27-million-gift/
GSCG established.. alliance.. HANK Bioengineering..Shenzhen, China
..Shenzhen HANK is a biotechnology company established in 2013 by Zhang, an award-winning scientist, microbiologist and virologist, to integrate research, development, production, and sales of biomedical products. Zhang worked at the U.S. Centers for Disease Control from 1991 to 1993, the U.S. National Institute of Health (NIH) from 1993 to 1994, and the U.S. Food and Drug Administration.. Scientific Achievement Award from the USFDA for outstanding achievement in natural killer (NK) cell research, and holds numerous awards for his work in the fields of HIV, HCV, West Nile virus, Japanese encephalitis virus, and quality performance.
..Dr. Zhang expanded on his work in stem cell research and development by launching HANK Bioengineering Co. Ltd. in Shenzhen, China. HANK is a 4,300 square foot (400 square meters) CFDA certified cGMP facility affiliated with HANK Bioengineering Institute’s Cell Biology and Molecular Immunology Laboratories. HANK has established close collaborations with more than five hospitals in China for clinical applications of its cell therapy products.
http://stemcellcenter.net/global-stem-cells-group-announces-alliance-with-hank-bioengineering-co-ltd-in-shenzhen-china/
Effect of NK cell immunotherapy on immune function in patients with hepatic carcinoma: A preliminary clinical study.
ZhangM3
..disease progression at 3 months after treatment was 18.8%, 50.0% and 31.2%, respectively. The total follow-up period was 2-12 months. The median progression-free survival from treatment was 7.5 months. This is the first study on the benefits of HANK cell immunotherapy for hepatic carcinoma These encouraging preliminary observations imply that HANK cell immunotherapy is safe, can improve the immune function of patients with liver cancer, and may even reduce the rate of tumor metastasis and recurrence...
https://www.ncbi.nlm.nih.gov/pubmed/28353401
..Stem Cell Center, Inc. is the world's largest collective support & advisory network of regenerative medicine clinics and and physicians
http://stemcellcenter.net/
Venture capitalists are betting big on one area of regenerative medicine
https://amp.businessinsider.com/venture-capital-interest-in-regenerative-medicine-2017-4
Money is pouring in to a hot new area of science that could change the way we think about aging
https://amp.businessinsider.com/venture-capital-interest-in-regenerative-medicine-2017-4
$LAHO GSCG All directions head to Money$$$
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
